Press "Enter" to skip to content

New patent for Boehringer Ingelheim drug PRADAXA

1
Copyright © DrugPatentWatch. Originally published at New patent for Boehringer Ingelheim drug PRADAXA

Annual Drug Patent Expirations for PRADAXA
Annual Drug Patent Expirations for PRADAXA

Pradaxa is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from three suppliers. There are five patents protecting this drug and two Paragraph IV challenges.

PRADAXA drug price trends.

Drug patent litigation for PRADAXA.

This drug has two hundred and forty-five patent family members in fifty-two countries.

The generic ingredient in PRADAXA is dabigatran etexilate mesylate. Three suppliers are listed for this compound. Additional details are available on the dabigatran etexilate mesylate profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Make Better Decisions with DrugPatentWatch

Get the Daily Briefing or Try a trial

Copyright © DrugPatentWatch. Originally published at New patent for Boehringer Ingelheim drug PRADAXA

Comments are closed.

Get the DrugPatentWatch Daily Briefing

✓ Patent Expirations and Generic Entry

✓ Insightful Articles & Case Studies

✓ Patent Litigation & Challenges

✓ 505(b)(2) & Biosimilars

✓ Industry Trends

DrugPatentWatch - Make Better Decisions